U.S. Senators Cory Booker and Elizabeth Warren have sent a letter to Attorney General Merrick Garland urging the Department of Justice to decriminalize cannabis by removing it from the federal controlled substances list.

Psychedelic stocks today are cash-rich with extremely attractive valuations. Blue-chip stocks sit with record debt levels and grossly inflated valuations. Advantage: psychedelic stocks.

The National Basketball Association has agreed to not randomly test players for cannabis during the upcoming season, continuing the policy which started during the “restart bubble” and was continued last season, the Associated Press reports.

A coalition of Pennsylvania lawmakers introduced a bill this week that’s meant to promote research into the therapeutic potential of psilocybin mushrooms for mental health conditions such as post-traumatic stress disorder —the latest example of how the psychedelics reform movement is gaining momentum.

Cannabis advocates in Oklahoma have filed ballot initiatives for 2022 to legalize adult-use cannabis and replace the current medical cannabis oversight agency, the Tulsa World reports.

Numinus announces expansion of its psychedelics research facility and an application to Health Canada for a second Dealer’s License.

Mydecine’s lead drug candidate, MYCO-001 will be used in a major, new smoking cessation clinical study by Johns Hopkins.

Seattle’s City Council approved a resolution Monday to decriminalize noncommercial activity around a wide range of psychedelic substances, including the cultivation and sharing of psilocybin mushrooms, ayahuasca, ibogaine and non-peyote-derived mescaline.

Psychedelic drugs like psilocybin, LSD and MDMA have amazing medicinal and commercial potential. So does ketamine, but ketamine is already legal.

Novamind is expanding its mental health care to include the treatment of patients with palliative needs, via its new Murray, Utah treatment clinic.